Type: therapy
Status: Investigational
Developer: Multiple (BioNTech-style)
Researchers developed an mRNA-based therapy that can prevent or significantly slow the onset of Type 1 diabetes by reprogramming immune cells. Builds on COVID-19 mRNA vaccine technology adapted for autoimmune disease.
mRNA-encoded tolerogenic antigens reprogram immune cells to stop attacking pancreatic beta cells
Year: 2026